La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Pharma Mar Bilan de santé
Santé financière contrôle des critères 4/6
Pharma Mar possède un total de capitaux propres de €181.4M et une dette totale de €36.3M, ce qui porte son ratio d'endettement à 20%. Son actif total et son passif total sont €317.1M et de €135.7M.
Informations clés
20.0%
Ratio d'endettement
€36.35m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | €135.15m |
| Fonds propres | €181.38m |
| Total du passif | €135.72m |
| Total des actifs | €317.10m |
Mises à jour récentes de la santé financière
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Recent updates
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Analyse de la situation financière
Passif à court terme: Les actifs à court terme de PHM ( €224.1M ) dépassent ses passifs à court terme ( €87.9M ).
Passif à long terme: Les actifs à court terme de PHM ( €224.1M ) dépassent ses passifs à long terme ( €47.8M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: PHM dispose de plus de liquidités que de sa dette totale.
Réduire la dette: PHM avait des capitaux propres négatifs il y a 5 ans, mais ils sont désormais positifs et se sont donc améliorés.
Couverture de la dette: Le flux de trésorerie opérationnel de PHM est négatif, par conséquent la dette n'est pas bien couverte.
Couverture des intérêts: Données insuffisantes pour déterminer si les paiements d'intérêts de PHM sur sa dette sont bien couverts par l'EBIT.